KALA

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

KALA BIO Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

KALA BIO Inc. EPS for the last quarter amounts to -1.07 USD, decreased -44.56 % YoY.

KALA BIO Inc (KALA) has 38 emplpoyees as of December 16 2025.

Today KALA has the market capitalization of 11.04M USD.